Syndax Pharmaceuticals (SNDX) Assets Average (2016 - 2026)

Syndax Pharmaceuticals' Assets Average history runs 11 years deep, the most recent figure standing at $501.2 million for Q1 2026.

• On a quarterly basis, Assets Average fell 26.59% year-over-year to $501.2 million in Q1 2026; TTM through Mar 2026 was $501.2 million, a 26.59% decrease from a year earlier, with the FY2025 full-year figure at $627.3 million, down 6.22% from the prior year.
• Assets Average fell to $501.2 million in Q1 2026 per SNDX's latest filing, from $540.7 million in the prior quarter.
• Across five years, Assets Average topped out at $682.8 million in Q1 2025 and bottomed at $383.1 million in Q3 2022.
• The 5-year median for Assets Average is $501.2 million (2026), against an average of $502.3 million.
• Across the five-year window, Assets Average jumped 52.68% in 2022 and retreated 26.59% in 2026, its largest moves.
• Year by year, Assets Average stood at $428.5 million in 2022, then climbed by 18.11% to $506.1 million in 2023, then rose by 13.69% to $575.3 million in 2024, then decreased by 6.01% to $540.7 million in 2025, then decreased by 7.32% to $501.2 million in 2026.
• Per Business Quant, the three latest SNDX Assets Average figures stand at $501.2 million (Q1 2026), $540.7 million (Q4 2025), and $574.0 million (Q3 2025).